同種異體移植市場－全球產業規模、佔有率、趨勢、機會、預測：按應用程式、類型、最終用戶、地區和競爭格局分類，2021-2031年

全球同種異體移植市場預計將從 2025 年的 14.8 億美元成長到 2031 年的 22.6 億美元，複合年成長率為 7.31%。

這些取自人體捐贈者的天然組織移植片對於修復骨骼缺損、治療骨折和輔助脊椎融合手術至關重要。市場擴張的主要驅動力是人口老化導致整形外科疾病發生率上升，以及需要重組手術的運動相關損傷病例增加。此外，由於避免了與二次供體部位相關的併發症，臨床上更傾向於使用異體移植片而非自體移植片，這也顯著促進了市場成長。組織處理技術的改進，在確保無菌的同時維持了生物完整性，進一步增強了外科醫生對這些生物解決方案的信心。然而，該市場面臨著許多挑戰，包括感染疾病傳播的風險，以及嚴格的法律規範和產品召回的可能性，這些都可能阻礙市場成長。嚴格的捐贈者篩檢對於確保這些產品的安全性至關重要，並且在需求高峰期供應可能有限。這種依賴性顯而易見，組織和生物製品促進協會預測，到2024年，每年將有約250萬例生技藥品移植手術，以改善患者的健康和活動能力。

市場促進因素

脊椎融合手術和關節重組手術數量的不斷成長是全球骨同種異體移植市場的主要驅動力。隨著人口老化，骨關節炎等退化性疾病率不斷上升，對提供結構支撐的同種異體移植組織的需求也隨之成長。外科醫生更傾向於使用這些生物植入，因為它們能夠在恢復患者活動能力的同時，避免自體移植帶來的併發症風險，因此得到了持續的推廣應用。產業數據也印證了手術量的激增。 Enobis公司報告稱，重組部門2024年的淨銷售額成長了59%，Zimmer Biomet公司同年也實現了76.8億美元的淨銷售額。這顯示市場對關節重組解決方案和整形外科產品有著強勁的需求。同時，再生醫學和生物植入的進步也透過提高骨移植的安全性和有效性，推動了市場成長。組織處理技術的創新，特別是細胞骨基質和先進滅菌技術的進步，已成功降低感染疾病傳播的風險，同時保持了對癒合至關重要的骨誘導能力。這些改進增強了臨床信心，並加速了複雜整形外科手術中高品質同種異體移植材料的使用。專注於這些先進生物製劑的公司所取得的商業性成功也印證了這個趨勢。 Orthofix Medical Inc.公佈2024會計年度全年淨銷售額為7.995億美元，較去年同期成長7%，主要得益於其脊椎和骨骼生長治療產品組合的強勁表現。

市場挑戰

疾病傳播風險是全球骨同種異體移植市場成長的一大障礙。病原體（如細菌和病毒）傳播的可能性使得對捐贈者進行嚴格篩檢和嚴格遵守相關法規成為必要，導致合格捐贈者數量大幅減少。這個篩選過程限制了原料的供應，造成供不應求，無法滿足日益成長的整形外科和脊椎手術臨床需求。此外，對污染事件及其導致的產品召回的擔憂會引發市場波動，並削弱外科醫生對同種異體移植安全性的信心。因此，與合成替代品相比，人們可能對採用同種異體移植猶豫不決。這種高度嚴格的監管環境對參與企業施加了巨大的營運限制。嚴格的合規要求提高了進入門檻，推高了營運成本，並阻礙了市場的快速擴張。管理這些風險所需的綜合基礎設施的重要性顯而易見，根據生技藥品和生物製品促進協會的數據，到 2025 年將有 120 多個獲得認證的組織庫投入運營，這凸顯了以安全為中心的法規如何直接限制了市場規模和數量的擴張。

市場趨勢

市場的一個顯著趨勢是，隨著外科醫生尋求兼具結構穩定性和增強成骨能力的移植材料，脫礦骨基質（DBM）製劑的應用日益廣泛。與標準的礦化同種異體移植材料不同，DBM經過酸提取處理，暴露出骨形成蛋白（BMP），從而促進複雜脊椎手術中的骨融合。因此，製造商正在開發具有更優異操作性能的先進DBM糊劑和條帶，以改善骨不連的手術效果。 Orthofix Medical Inc.的骨生長治療部門的表現反映了這一需求，該部門在2025年第三季度實現了6,120萬美元的淨銷售額，同比成長6%。同時，在美學牙科修復中保持健康齒槽嵴的需求也推動了同種異體骨移植在人工植牙領域的應用不斷擴展。外科醫生擴大在諸如鼻竇增高術和牙槽窩保存術等手術中使用顆粒狀和塊狀同種異體移植材料，以維持骨量並增強植入的穩定性，而無需進行二次取骨。這一趨勢的進一步推動因素是針對特定牙周缺損進行精準匹配的專用同種異體移植材料的出現，這些材料簡化了椅旁操作流程。受此領域成長的推動，士卓曼集團2024年全年銷售額達到25億瑞士法郎，實現13.7%的內部成長，這主要得益於市場對高階植入和再生醫學解決方案的持續需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球同種異體移植市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依應用領域（牙科、脊椎外科、重組/創傷外科、其他）
  • 依類型（皮質骨同種異體移植、鬆質骨同種異體移植、皮質鬆質骨同種異體移植、脫礦骨基質）
  • 依最終使用者（醫院/牙醫診所、整形外科/創傷中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美同種異體移植市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲同種異體移植市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區同種異體移植市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲同種異體骨市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲同種異體移植市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球同種異體移植市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zimmer Biomet inc.
• Medtronic inc.
• Lynch Biologics, LLC
• Biomatlante SA
• Stryker Corporation
• Royal Biologics, Inc.
• Johnsons & Johnsons
• Smith & Nephew plc
• Baxter International Inc
• Xtant Medical Holdings

第16章 策略建議

第17章：關於研究公司及免責聲明

The global bone allografts market is projected to expand from USD 1.48 billion in 2025 to USD 2.26 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 7.31%. These natural tissue grafts, sourced from human donors, are critical for repairing skeletal defects, treating fractures, and supporting spinal fusions. Market expansion is primarily fueled by a growing elderly population, which elevates the incidence of orthopedic conditions, alongside an increase in sports-related injuries necessitating reconstructive surgeries. Furthermore, the clinical preference for allografts over autografts, due to the elimination of complications associated with a secondary surgical harvest site, contributes significantly to this growth. Enhanced tissue processing technologies, which maintain biological integrity while ensuring sterility, further boost surgeon confidence in these biological solutions. Nevertheless, the market faces a substantial challenge from the risk of disease transmission, which could hinder growth due to stringent regulatory oversight and the potential for product recalls. Ensuring the safety of these products mandates rigorous donor screening, occasionally restricting supply during peak demand. This reliance is evident, as approximately 2.5 million tissue transplants were performed annually in 2024 to improve patient health and mobility, according to the Association for Advancing Tissue and Biologics.

Market Driver

The increasing volume of spinal fusion and joint reconstruction procedures serves as a primary catalyst for the Global Bone Allografts Market. As the aging population experiences more degenerative conditions like osteoarthritis, the demand for surgical interventions, and consequently for allograft tissues providing structural support, escalates. Surgeons favor these biological implants for their ability to restore patient mobility without the morbidity linked to autograft harvesting, leading to sustained adoption. This procedural surge is corroborated by industry data; Enovis Corporation reported a 59% growth in net sales for its Reconstructive segment in 2024, and Zimmer Biomet achieved $7.68 billion in net sales for the same year, indicating robust demand for joint reconstruction solutions and orthopedic products. Simultaneously, advancements in regenerative medicine and bio-implants are propelling market growth by enhancing the safety and efficacy of bone grafting. Innovations in tissue processing, specifically in cellular bone matrices and advanced sterilization, have successfully reduced disease transmission risks while preserving the crucial osteoinductive properties vital for healing. These improvements foster greater clinical confidence, encouraging a transition toward high-quality allografts in complex orthopedic surgeries. The commercial success of companies focusing on these advanced biologics validates this trend, with Orthofix Medical Inc. recording full-year 2024 net sales of $799.5 million, marking a 7% increase driven by strong performance in its spine and bone growth therapy portfolios.

Market Challenge

The risk of disease transmission represents a significant impediment to the growth of the Global Bone Allografts Market. The potential for transmitting pathogens such as bacteria or viruses necessitates rigorous donor screening and strict regulatory adherence, which critically reduces the pool of eligible donors. This exclusionary process limits the availability of raw materials, creating supply shortages that often fail to meet the increasing clinical demand for orthopedic and spinal procedures. Moreover, the apprehension surrounding contamination events and subsequent product recalls introduces market volatility and can diminish surgeon confidence in allograft safety, potentially causing a hesitation in their adoption compared to synthetic alternatives. This environment of heightened scrutiny imposes substantial operational constraints on market players, with the need for meticulous compliance establishing high barriers to entry and elevating operational costs, thus hindering rapid market expansion. The consolidated infrastructure required to manage these risks is highlighted by the more than 120 accredited tissue banks operating in 2025, according to the Association for Advancing Tissue and Biologics, underscoring how safety-driven regulations directly limit the market's capacity to scale operations and volume.

Market Trends

A notable trend transforming the market is the increasing adoption of Demineralized Bone Matrix (DBM) formulations, as surgeons seek grafts combining structural stability with enhanced osteoinductive potential. Unlike standard mineralized allografts, DBM undergoes acid extraction to expose bone morphogenetic proteins (BMPs), which accelerates fusion in complex spinal procedures. Consequently, manufacturers are developing advanced DBM putties and strips with superior handling characteristics to improve surgical outcomes in non-union fractures, a demand reflected in Orthofix Medical Inc.'s Bone Growth Therapies segment achieving net sales of $61.2 million in Q3 2025, a 6% increase year-over-year. Concurrently, the expansion of allograft applications in dental implantology is becoming a critical trajectory, driven by the necessity for robust alveolar ridge preservation in esthetic tooth replacement. Surgeons are increasingly utilizing particulate and block allografts for procedures like sinus lifts and socket preservation to maintain bone volume and support implant stability without requiring secondary harvesting. This trend is further supported by application-specific allograft shapes designed to fit precise periodontal defects, streamlining chairside workflows. Validating this sector's growth, Straumann Group's 2024 full-year revenue reached CHF 2.5 billion, with 13.7% organic growth, propelled by sustained demand for premium implantology and regenerative solutions.

Key Market Players

• Zimmer Biomet inc.
• Medtronic inc.
• Lynch Biologics, LLC
• Biomatlante S.A
• Stryker Corporation
• Royal Biologics, Inc.
• Johnsons & Johnsons
• Smith & Nephew plc
• Baxter International Inc
• Xtant Medical Holdings

Report Scope

In this report, the Global Bone Allografts Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Allografts Market, By Application

• Dental
• Spine
• Reconstruction & Traumatology
• Others

Bone Allografts Market, By Type

• Cortical Bone Allografts
• Cancellous Bone Allografts
• Corticocancellous Bone Allografts
• Demineralized bone Matrices

Bone Allografts Market, By End-user

• Hospitals & Dental Clinics
• Orthopedic & Trauma Centers
• Others

Bone Allografts Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Allografts Market.

Available Customizations:

Global Bone Allografts Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bone Allografts Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Dental, Spine, Reconstruction & Traumatology, Others)
  • 5.2.2. By Type (Cortical Bone Allografts, Cancellous Bone Allografts, Corticocancellous Bone Allografts, Demineralized bone Matrices)
  • 5.2.3. By End-user (Hospitals & Dental Clinics, Orthopedic & Trauma Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Bone Allografts Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Type
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bone Allografts Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End-user
  • 6.3.2. Canada Bone Allografts Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End-user
  • 6.3.3. Mexico Bone Allografts Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End-user

7. Europe Bone Allografts Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Type
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bone Allografts Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End-user
  • 7.3.2. France Bone Allografts Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End-user
  • 7.3.3. United Kingdom Bone Allografts Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End-user
  • 7.3.4. Italy Bone Allografts Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End-user
  • 7.3.5. Spain Bone Allografts Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End-user

8. Asia Pacific Bone Allografts Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Type
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bone Allografts Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End-user
  • 8.3.2. India Bone Allografts Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End-user
  • 8.3.3. Japan Bone Allografts Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End-user
  • 8.3.4. South Korea Bone Allografts Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End-user
  • 8.3.5. Australia Bone Allografts Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End-user

9. Middle East & Africa Bone Allografts Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Type
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bone Allografts Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End-user
  • 9.3.2. UAE Bone Allografts Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End-user
  • 9.3.3. South Africa Bone Allografts Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End-user

10. South America Bone Allografts Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Type
  • 10.2.3. By End-user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bone Allografts Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End-user
  • 10.3.2. Colombia Bone Allografts Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End-user
  • 10.3.3. Argentina Bone Allografts Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bone Allografts Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zimmer Biomet inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Medtronic inc.
• 15.3. Lynch Biologics, LLC
• 15.4. Biomatlante S.A
• 15.5. Stryker Corporation
• 15.6. Royal Biologics, Inc.
• 15.7. Johnsons & Johnsons
• 15.8. Smith & Nephew plc
• 15.9. Baxter International Inc
• 15.10. Xtant Medical Holdings

16. Strategic Recommendations

17. About Us & Disclaimer